Claritev vs Nutex Health
CTEV and NUTX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTEV and NUTX compare
Nutex Health is the larger company, worth 2.7 times as much as Claritev ($1.3B against $478M).
Claritev grew revenue faster over the last twelve months (6.9% versus −18.8% for Nutex Health).
Nutex Health keeps more of each dollar of sales as profit, with a net margin of 20.7% compared with −27.1% at Claritev.
Nutex Health scores higher on the StockData Score (15 against 4 for Claritev), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTEV | NUTX |
|---|---|---|
| Size and price | ||
| Market cap | $478M | $1.3B |
| Share price | $28.21 | $189.19 |
| Change, 1 year | −51.2% | 59.2% |
| Change, 5 years | −80.0% | −69.6% |
| Beta (5Y) | 1.24 | 1.86 |
| Employees | 3,000 | 944 |
| StockData Score | ||
| Total score | 4 | 15 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 8.1× |
| P/S | 0.5× (better) | 1.6× |
| P/B | – | 3.0× |
| EV/EBITDA | 118× | 3.6× (better) |
| P/FCF | – | 5.2× |
| FCF yield | −5.8% | 19.1% (better) |
| Fair value | – | $570.15 |
| Margin of safety | – | 66.8% |
| Growth | ||
| Revenue growth (TTM) | 6.9% (better) | −18.8% |
| Revenue growth, 5Y average | 0.58% | 26.1% (better) |
| Net income growth (TTM) | – | 36.5% |
| EPS growth (TTM) | – | 21.2% |
| EPS growth, 5Y average | – | −17.2% |
| Profitability | ||
| Gross margin | 72.8% (better) | 47.8% |
| Operating margin | 4.2% | 39.0% (better) |
| Net margin | −27.1% | 20.7% (better) |
| FCF margin | −2.7% | 31.1% (better) |
| Return on equity | – | 43.8% |
| Return on invested capital | 0.78% | 117% (better) |
| Financial health | ||
| Debt / equity | – | 0.10 |
| Net debt / EBITDA | 107.00 (better) | −0.62 |
| Interest coverage | 0.1× | 16.2× (better) |
| Current ratio | 1.15 | 4.76 (better) |
| Altman Z-score | −0.47 | 3.75 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.38% | 4.3% (better) |
| Shareholder yield | −0.38% | 4.3% (better) |
| Ownership | ||
| Held by institutions | 91.0% | 42.9% |
| Held by insiders | 50.2% | – |
| Insider net buying, 12 months | $4.0M (better) | $2.2K |
| Short interest, % of float | 9.1% | – |
Go deeper
- CTEV stock overview
- CTEV income statement
- CTEV valuation and score
- NUTX stock overview
- NUTX income statement
- NUTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.